Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc.

Overview
Headquarters

184 LIBERTY CORNER ROAD SUITE 302 WARREN NJ 07059

Type of Company

Public

Employees (Worldwide)

17

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services

Company Description

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Contact Data
Trying to get in touch with decision makers at Bellerophon Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer, Secretary & Principal Accounting Officer

Vice President & Chief Business Officer

Acting Chief Medical Officer

Principal Financial Officer

Vice President, Engineering & Manufacturing

Vice President, Clinical Operations & Administration

Vice President, Business Operations

Safety Officer

Interim Chairman & Chief Executive Officer

Board of Directors

Co-Founder at Arix Bioscience Plc

Former Senior Partner at PricewaterhouseCoopers LLP

Managing Director at New Mountain Capital LLC

Chief Investment Officer at Puissance Capital Management GP LLC

Managing Director at New Mountain Capital LLC

Chief Executive Officer & Director at GMP-Orphan SA

Professor at Case Western Reserve University

Benefit Plan Administrator at Lincare, Inc.

Chief Executive Officer at Bellerophon Therapeutics, Inc.

Paths to Bellerophon Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Bellerophon Therapeutics, Inc.
Owners & Shareholders
Details Hidden

New Mountain Vantage Advisers, LLC ("Vantage") is a U.S. SEC-registered investment adviser designed to apply the Firm's strengths in research and business building to non-control positions in the U.S. public equity marketplace. Vantage seeks to invest in both long and short equity positions based on bottom-up fundamental research, concentrating on companies and industries which it deems to be most attractive. It may also employ dynamic derivative strategies with the goals of protecting capital during market corrections, reducing volatility, and enhancing returns. New Mountain's public equity investment approach is overseen by a dedicated team within New Mountain, which then draws upon all other team members and resources of the Firm in their areas of specialty. New Mountain believes that the skills and experience of the public equity team, coupled with the full hands-on operational and research expertise of a multi-billion dollar private equity firm, give Vantage competitive advantages over traditional, stand-alone public equity investment managers that lack such operating, acquisition and control ownership experience. Since Vantage advises a private fund, New Mountain is limited in the amount of information it can provide on this website. However, additional and more specific information may be made available to accredited investors and/or qualified purchasers (and individuals that represent them) upon request.

Details Hidden

Puissance Capital Management LP is an American private company headquartered in New York, NY, with a presence in several countries, that provides investment advice. The firm was founded in 2015 by Theodore Wang, who has been the CEO since then.

Details Hidden

VHCP Management focuses on investments in the stocks of US and European small-cap companies in the health technology sector.

Recent Transactions
Details Hidden

Bellerophon Therapeutics, Inc. issued USD Common Stock

Details Hidden

Bellerophon Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Bellerophon Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onBellerophon Therapeutics, Inc. issued Common Stock

Investment Advisor

Advised onBellerophon Therapeutics, Inc. raised money in a private placement transaction

Escrow Agent

Advised onBellerophon Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onBellerophon Therapeutics, Inc. issued Common Stock

Legal Advisor

Advised onBellerophon Therapeutics, Inc. issued Common Stock

Attorney

Advised onBellerophon Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Managing Director at LifeSci Advisors LLC

Publicist

Founder at RX Communications Group LLC

Key Stats and Financials As of 2018
Market Capitalization
$44.8M
Total Enterprise Value
$35.4M
Earnings Per Share
$0.04
Revenue
$0
Net Profit
$2.81M
EBITDA
$-27.5M
Total Debt
$0
Total Equity
$3.86M
TEVNet Income
12.57x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

Venrock helps entrepreneurs build some of the world's most disruptive, successful companies. They partner with entrepreneurs who have grand ambitions and help's them in almost every dimension of building their company: hiring, strategy, financing, scaling, introductions and managing a great exit. The firm targets to invest in companies operating in the fields of technology & health care sectors and provides financing for early stage capital requirements.

Details Hidden

Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments.They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects.The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.

Details Hidden

5AM Ventures focuses on building next-generation life science companies capable of delivering outstanding returns to their investors. the firm support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. their portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions. the firm employs a time-tested, hands-on approach to company-building and, in addition to being an early investor, they often involve in setting company strategy, management recruiting, business development and fundraising. they contribute as board members and frequently take on short-term operating roles.

Suppliers
BioLineRX Ltd. Pharmaceuticals | Jerusalem, JM

BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Mallinckrodt Plc Pharmaceuticals | Staines-Upon-Thames, SU

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.

Flex Ltd. Engineering, Construction & Architecture | Singapore, CE

At Flextronics, impossible is where breakthrough begins. As a socially-responsible, global leader in design, manufacturing, distribution and aftermarket services, Flextronics is unique in its ability to provide end-to-end solutions through its innovative and proprietary systems — all to enhance customer competitiveness and success. Working across four business groups and several business units, Flextronics is able to unleash the full potential of the world’s most valuable brands and new ventures. What Flextronics creates is value. By increasing speed to market and driving competitive positioning for customers, Flextronics in essence solves customers’ most challenging problems better, faster and more cost effectively than any other company. Flextronics is able to manage big data in a way that allows for trending in market environments that are in flux, allowing the Company to provide solutions for customers, often before a challenge is ever realized. Flextronics is unique in the depth, breadth and scope of the Company. With an unmatched global presence, customers are supported with unprecedented speed in product ramp-up, delivery, and the ability to manage volume regardless of complexity or product mix. Leveraging state-of-the-art LEAN practices, Six Sigma, key investments in infrastructure and FlexQ, a propriety quality program that is beyond leading edge according to customers, Flextronics is the market leader in almost every business in which it operates. Whether high mix/low volume or low mix/high volume, Flextronics can enable any customer's success. At Flextronics, there is no room for “mediocrity.” If anything, the Company exists to continually test the bounds of what can be expected in terms of designs and processes. Optimization is what Flextronics does best. People make the difference. People with passion have an even greater impact. The Flextronics team spans 30 countries and four continents, and is over 200,000 people strong. Each member of the team is dedicated to enabling customer success. That is achieved through intense collaboration, passionate customer focus, thoughtful and disciplined execution, a tenacious commitment to continuous improvement and a relentless drive to win. Culture is the most important sustainable, competitive advantage of any company. The Flextronics culture is built on commitment — to customers, employees, the communities in which it operates and the environment. Flextronics is a global leader in non-profit/for-profit partnership, providing assistance in the places around the world that need it most. The Flextronics Foundation provides assistance in the areas of natural disaster relief, health and wellness initiatives and educational opportunities. Culture drives every aspect of the Company’s success. The culture and business model work hand-in-hand to ensure simplicity, flexibility and above all — sustainability.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bellerophon Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bellerophon Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Bellerophon Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/bellerophon-therapeutics-inc-132423577
  • https://relationshipscience.com/organization/bellerophon-therapeutics-inc-132423577